<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12633909
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     03
    </month>
    <day>
     13
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     10
    </month>
    <day>
     29
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0376-8716
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       69
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        Apr
       </month>
       <day>
        1
       </day>
      </pubdate>
     </journalissue>
     <title>
      Drug and alcohol dependence
     </title>
     <isoabbreviation>
      Drug Alcohol Depend
     </isoabbreviation>
    </journal>
    <articletitle>
     Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur.
    </articletitle>
    <pagination>
     <medlinepgn>
      233-41
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      In 1994, the Drug Abuse Advisory Committee (DAAC) of the Food and Drug Administration (FDA) concluded that Ultram (tramadol hydrochloride) could be marketed as an analgesic drug without scheduling under the Controlled Substances Act based upon extensive pre-clinical, clinical and European epidemiological data. However, to guard against unexpectedly high levels of abuse in the United States, the DAAC recommended that an independent steering committee (ISC) be appointed to proactively monitor abuse/dependence. In the event that high rates of abuse were found, this ISC was given the authority to immediately recommend to the FDA that Ultram be scheduled. In the course of the surveillance project, the ISC received reports of withdrawal following abrupt discontinuation of Ultram and in some instances, following dose reductions. In most cases, the withdrawal symptoms consisted of classical opioid withdrawal, but in some cases were accompanied by withdrawal symptoms not normally observed in opiate withdrawal, such as hallucinations, paranoia, extreme anxiety, panic attacks, confusion and unusual sensory experiences such as numbness and tingling in one or more extremities. Withdrawal symptoms of either type were one of the more prevalent adverse events associated with chronic Ultram use, comprising nearly 40% of all adverse events reported with Ultram. Most of these consisted of typical opiate withdrawal symptoms, but 1 in 8 cases presented as atypical. These results indicate that physicians and other healthcare professionals need to be aware of the potential of Ultram to induce withdrawal of the classical opioid type, and that atypical withdrawal may also occur.
     </abstracttext>
    </abstract>
    <affiliation>
     Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Senay
      </lastname>
      <forename>
       Edward C
      </forename>
      <initials>
       EC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Adams
      </lastname>
      <forename>
       Edgar H
      </forename>
      <initials>
       EH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Geller
      </lastname>
      <forename>
       Anne
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Inciardi
      </lastname>
      <forename>
       James A
      </forename>
      <initials>
       JA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Mu√±oz
      </lastname>
      <forename>
       Alvaro
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Schnoll
      </lastname>
      <forename>
       Sidney H
      </forename>
      <initials>
       SH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Woody
      </lastname>
      <forename>
       George E
      </forename>
      <initials>
       GE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cicero
      </lastname>
      <forename>
       Theodore J
      </forename>
      <initials>
       TJ
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     Ireland
    </country>
    <medlineta>
     Drug Alcohol Depend
    </medlineta>
    <nlmuniqueid>
     7513587
    </nlmuniqueid>
    <issnlinking>
     0376-8716
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Analgesics, Opioid
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      27203-92-5
     </registrynumber>
     <nameofsubstance>
      Tramadol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adverse Drug Reaction Reporting Systems
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Analgesics, Opioid
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug and Narcotic Control
     </descriptorname>
     <qualifiername majortopicyn="N">
      legislation &amp; jurisprudence
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Opioid-Related Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      rehabilitation
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Psychoses, Substance-Induced
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Substance Withdrawal Syndrome
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tramadol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      United States
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      United States Food and Drug Administration
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      3
     </month>
     <day>
      14
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      10
     </month>
     <day>
      30
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      3
     </month>
     <day>
      14
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12633909
    </articleid>
    <articleid idtype="pii">
     S0376871602003216
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

